Glenmark Pharmaceuticals rose 1.10% to Rs 465 after the company received final approval from the US drug regulator for diltiazem hydrochloride extended‐release capsules.
The product is the generic version of Cardizem SR extended‐release capsules, 60 mg, 90 mg, and 120 mg, of Biovail Laboratories Inc. The drug is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medications.
Glenmark Pharmaceuticals has been granted a competitive generic therapy (CGT) designation for diltiazem hydrochloride extended‐release capsules USP, 60 mg, 90 mg, and 120 mg, therefore, with this approval, the pharmaceutical major has become the first approved applicant for such competitive generic therapy and is eligible for 180 days of CGT exclusivity upon commercial marketing.
According to IQVIA figures, the sales data for the 12-month period ending January 2021, the Cardizem SR Extended‐Release capsules, 60 mg, 90 mg, and 120 mg market2 achieved annual sales of approximately $56.7 million.
Glenmark Pharmaceuticals' current portfolio consists of 170 products authorized for distribution in the U.S. marketplace and 42 ANDA's pending approval with the United States Food and Drug Administration (USFDA). In addition to these internal filings, Glenmark Pharmaceuticals continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
The announcement was made before market hours today, 23 March 2021. Yesterday, Glenmark Specialty S.A. in Switzerland and an affiliate of Bausch Health Companies Inc. had entered into an exclusive licensing agreement for the commercialization of Glenmark Pharma.'s innovative nasal spray Ryaltris, under review by Health Canada.
Glenmark Pharma's consolidated net profit jumped 30% to Rs 248.18 crore on 4.6% increase in net sales to Rs 2,758.74 crore in Q3 December 2020 over Q3 December 2019.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across generics, specialty and over-the-counter (OTC) business with operations in over 50 countries. Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU